Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text

Medicine, Clinical Sciences, Oncology +12

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Caroline Robert, Georgina V. Long, Benjamin Brady et al. · New England Journal of Medicine · 2014 · 5.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Caroline Robert, L. Thomas, Igor Bondarenko et al. · New England Journal of Medicine · 2011 · 4.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +12